First coverage of Tango Therapeutics: Innovation pipeline leads revolution, given positive rating (J.P. Morgan)
J.P.
J.P. The ORR of the core asset vopimetostat combined with a RAS inhibitor in the treatment of pancreatic cancer is as high as 92%, and the 6-month PFS rate is 90%. The data is extremely amazing. This means that the drug is expected to become a blockbuster drug for the treatment of refractory cancers such as KRAS mutated pancreatic cancer, and the company's value is extremely high. The market may have reservations about this early, small-sample data, but its effectiveness far exceeds that of existing treatments and is enough to arouse great concern. The company also has several recent clinical catalysts. Bottom line: Tango's vopimetostat demonstrated transformative efficacy data when combined with a RAS inhibitor, making it one of the most promising biotech companies in therapeutic areas such as pancreatic cancer. Positive/negative: This is a major positive for Tango Therapeutics (TNGX.US) and boosts sentiment in the entire PRMT5 inhibitor track. The current stock price may not fully reflect the forward value of its pipeline assets, and there is a huge expectation gap. Catalysts: 1) Detailed data on the NSCLC cohort to be released in 2H26; 2) Further expansion of combination drug cooperation with Merck and other pharmaceutical companies; 3) Progress in clinical advancement to registration trials.